Oblita Therapeutics

Oblita Therapeutics is a biotechnology company dedicated to developing first-in-class small molecule inhibitors for historically undruggable oncogenic targets, with a primary focus on the MYC transcription factor. The company leverages structural biology and fragment-based drug discovery to disrupt the interaction between MYC and its essential co-factor, WD repeat-containing protein 5 (WDR5). By inhibiting this critical protein-protein interaction, Oblita aims to treat a wide range of MYC-driven cancers, including both solid tumors and hematologic malignancies. Their pipeline is currently in the pre-clinical stage, advancing candidates toward IND-enabling studies.